高效免疫抑制剂治疗溃疡性结肠炎的临床研究

High-performance lmmunosuppressant in the Treatment of Ulcerative Colitis：Clinical Study

为观察高效免疫抑制剂用于治疗溃疡性结肠炎（UC）的可行性，我院应用吗替麦考酚酯分散片（M组）、他克莫司胶囊（T组）、环孢素软胶囊（C组）口服治疗UC患者各100例，并对患者的耐受性、服药后的不良反应、疾病活动指数（DAI）、内镜下肠黏膜改善情况进行疗效评价。结果显示，3组患者中因药物不耐受或出现不良反应等而遐出研究49例，其中M组9例（9．0％），T组30例（30．0％），C组10例（10．0％）。3组患者出现的不良反应都是可逆性的，停药后均很快恢复。3组患者治疗后DAI评分均明显降低，P〈0．05。M组、T组和C组内镜下肠黏膜完全缓解率分别为60．4％（55／91）、51．4％（36／70）和45．6％（41／90）。结果表明，高效免疫抑制剂治疗UC疗效肯定，而且安全性高，为UC的药物治疗提供了又一途径。

In order to explore the feasibility of high performance immunosuppressants for treating ulcerative colitis （UC）,author＇s hospital adopted mycophenolate mofetil tablet,tacrolimus capsule and cyclospo- rine soft capsule to treat 300 cases of UC,100 cases for each,namely as group M,group T and group C; then observed the patient＇s tolerance,adverse reaction,disease activity index（DAD and improvement status of intestinal mucosa membrance under microscope, etc, and evaluated therapeutic effects of the three groups. As results,owing to non-tolerance and adverse reaction 9 cases （9.0%） in group M,30 （30.0%） in group T and 10（10.0%） in group C,total 49 cases withdrawed from this study;the patient＇s adverse reac- tions in three groups were reversible,i, e after stopping drugs them just disappeared fast,after treatment DAI ratings of the three groups were reduced significantly（ P 〈0.05）;the complete remission rate of intestinal mucosa membrance under microscope of group M,T,C just was 60.4% （55/91） ,51.4% （36/70）, 45.6%（41/90）,respectively. Results show that high-performance immunosuppressant in the treatment of UC has certain therapeutic effect and high safety, thereby offered a novel pathway for medication of UC.